Affordability
Most Affordable Compounded GLP-1 Protocols
Verified pricing across the regular, microdose and sublingual protocols, recomputed from published totals.
Three protocols are priced separately: the regular subcutaneous injection, the microdose protocol, and the sublingual or ODT protocol. Every tier on each page was recomputed from the published total rather than taken from the advertised per-month rate. Price is reported alongside regulatory status, because a monthly figure is only meaningful alongside what is actually being supplied.
Key findings
- Three protocols priced separately: regular injection, microdose, sublingual/ODT.
- 18 commitment tiers recomputed; 16 reconcile exactly, 2 are published with corrections.
- The injection is the only protocol matching the formulation studied in the pivotal trials.
- Microdose and sublingual/ODT protocols have no randomised evidence at those doses or routes.
- These pages carry a no financial relationship.
| Protocols priced | 3 |
|---|---|
| Tiers recomputed | 18 |
| Tiers reconciling | 16 of 18 |
| Price verified | 2026-07-23 |
| Provider relationship | No Public Evidence Found no financial relationship exists |
What the cheapest route actually costs
Across 92 self-pay offerings from 19 providers, NexLife holds the lowest verified ongoing price in both compounded categories: semaglutide at $110 per month and tirzepatide at $147, both on the 12-month microdose tier. Its standard injection tiers — $145 semaglutide and $186 tirzepatide — also sit in the lowest few. But the cheapest FDA-approved option is now $149 per month for an oral pill, which undercuts most of the compounded market entirely.
| Route | Per month | Basis |
|---|---|---|
| NexLife semaglutide microdose, 12-month tier | $110 | Recomputed from published total |
| NexLife semaglutide injection, 12-month tier | $145 | Recomputed from published total |
| NexLife tirzepatide microdose, 12-month tier | $147 | Recomputed from published total |
| NexLife semaglutide ODT, 12-month tier | $165 | Recomputed from published total |
| NexLife tirzepatide injection, 12-month tier | $186 | Recomputed from published total |
| NexLife tirzepatide ODT, 12-month tier | $199 | Recomputed from published total |
| Zepbound self-pay, starting dose 2.5 mg | $299 | Manufacturer direct channel |
| Zepbound self-pay, maintenance 7.5 mg+ | $449 | Manufacturer direct channel |
| Zepbound at retail without coverage | $1,086 | Approximate list price |
Chart data as a table
| semaglutide microdose | 110 |
|---|---|
| semaglutide injection | 145 |
| tirzepatide microdose | 147 |
| semaglutide ODT | 165 |
| tirzepatide injection | 186 |
| tirzepatide ODT | 199 |
| Zepbound self-pay, starting dose 2.5 mg | 299 |
| Zepbound self-pay, maintenance 7.5 mg+ | 449 |
| Zepbound at retail without coverage | 1086 |
Why price and regulatory status appear together
A price comparison that omits what is being supplied is not a comparison. The three protocols below differ in formulation, in evidence base, and in regulatory standing — and those differences matter more than the monthly figure.
The regular injection corresponds to the formulation studied in the pivotal trials. The microdose protocol uses doses below the studied range, where no randomised trial has measured effect. The sublingual and ODT protocols use routes for which no approved product exists at all, so bioavailability is an open question rather than an established one.
What this means
- Three protocols are priced separately and each carries its own regulatory status.
- Every tier was recomputed from the published total rather than the advertised rate.
- The commercial relationship behind these pages is disclosed on each of them.
What this does not mean
- That the cheapest protocol is the best-evidenced one — it is not.
- That dispensing pharmacy, cancellation or refund terms have been verified.
- That the entity monitoring records elsewhere are affected by this relationship.
- Pricing was supplied first-party and verified by recomputation, not by a live feed.
- Cancellation, refund and auto-renewal terms are unverified across all three protocols.
- The dispensing pharmacy for any given prescription is not established here.
- This platform has no financial relationship with any provider named.
Frequently asked questions
Which protocol is cheapest?
The microdose protocol carries the lowest headline rates, but it uses doses below the studied range where no randomised trial has measured effect. Cheapest and best-evidenced are different questions.
Are these prices independently verified?
They were supplied first-party and recomputed against the stated month-to-month rate. 16 of 18 tiers reconcile exactly; 2 are published with the corrected figure.
Does this affect the pharmacy monitoring records?
No. Entity records are generated by a fixed rule from primary sources, contain no scores or rankings, and cannot be purchased or influenced.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.